Skip to main content

Table 3 Type and schedules of adjuvant chemotherapy prescribed (n = 1095)

From: Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study

Type of chemotherapy

N (%)

CMF-like

100 (9.1)

· Anthracyclines alone (without Taxanes)

534 (48.8)

· Anthracyclines plus Taxanes

420 (38.4)

· Taxanes alone (without Anthracyclines)

41 (3.7)

Type of Taxane

 

· Docetaxel

359 (32.8)

· Paclitaxel

102 (9.3)

Main chemotherapeutic schedules administered

 

· Oral classical CMF 6 cycles

24 (2.2)

· CMF 6 cycles iv day 1 and 8 q28d

53 (4.8)

· CMF 6 cycles iv day 1 q21d

9 (0.8)

· CMF 3–4 cycles iv day 1 and 8 q28d

11 (1.0)

· AC 4 cycles

89 (8.1)

· AC 6 cycles

27 (2.5)

· E90C 4 cycles

56 (5.1)

· E75C 4 cycles

9 (0.8)

· FE75C 6 cycles

131 (12.0)

· FE90C 6 cycles

95 (8.7)

· FE100C 6 cycles

29 (2.6)

· FAC 6 cycles

8 (0.7)

· Canadian CEF 6 cycles

16 (1.5)

· Epidoxorubicin 4 cycles – CMF 4 cycles

5 (0.5)

· AC 4 cycles – CMF 3 cycles

15 (1.4)

· FEC 3 cycles - Docetaxel 3 cycles

118 (10.8)

· AC/EC 4 cycles - Docetaxel 4 cycles

127 (11.6)

· TAC 6 cycles + G-CSF

29 (2.7)

· AC/EC 4 cycles - Paclitaxel q3wks 4 cycles

39 (3.6)

· FEC/EC 4 cycles - weekly Paclitaxel x 12

43 (3.9)

· A/EP 4 cycles – CMF 4 cycles

7 (0.6)

· ET 6 cycles

12 (1.1)

· TC 4 cycles

19 (1.7)

· TC 6 cycles

8 (0.7)

· Others

116 (10.6)

  1. C = Cyclophosphamide; M = Methotrexate; F = Fluorouracil; A = Doxorubicin; E = Epirubicin; P = Paclitaxel; T = Docetaxel.